Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C
BackgroundRisk factors that influence the outcome of patients with chronic hepatitis C (CHC) are not fully understood. The systemic immune-inflammatory index (SII) is an independent prognostic factor for multiple diseases. However, the impact of the SII on the outcome of liver fibrosis is unclear.Me...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1486503/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161950836654080 |
|---|---|
| author | Yuanji Ma Jiayi Wang Lingyao Du Hong Tang |
| author_facet | Yuanji Ma Jiayi Wang Lingyao Du Hong Tang |
| author_sort | Yuanji Ma |
| collection | DOAJ |
| description | BackgroundRisk factors that influence the outcome of patients with chronic hepatitis C (CHC) are not fully understood. The systemic immune-inflammatory index (SII) is an independent prognostic factor for multiple diseases. However, the impact of the SII on the outcome of liver fibrosis is unclear.MethodsThis prospective real-world study enrolled patients with CHC treated with sofosbuvir/velpatasvir. Logistic regression models were used to investigate the relationship between the SII and the outcome of liver fibrosis in treatment-naive patients. Liver fibrosis was assessed using aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4).ResultsOf the 288 participants, the SII was 238.2 (153.0–358.2). The non-improved outcomes of liver fibrosis assessed with APRI (non-improved APRI) and FIB-4 (non-improved FIB-4) were 83.0 and 87.5%, respectively. Adjusted models showed that the SII was positively associated with non-improved APRI (adjusted OR (95% CI): 1.013 (1.009–1.017), p < 0.001) and FIB-4 (adjusted OR (95% CI): 1.004 (1.001–1.007), p = 0.012). Similarly, a higher SII was associated with a higher risk of non-improved APRI (adjusted OR (95% CI): 13.53 (5.60–32.68), p < 0.001) and FIB-4 (adjusted OR (95% CI): 5.69 (2.17–14.90), p < 0.001). The association with non-improved APRI was much more remarkable in patients with alanine aminotransferase <2 ULN, and the association with non-improved FIB-4 was remarkable in patients aged <50 years. Multiple imputation analyses confirmed the robustness of these results.ConclusionOur findings suggested that the SII was positively associated with non-improved outcomes of liver fibrosis in patients with CHC. These results need to be validated in large-scale prospective cohorts. |
| format | Article |
| id | doaj-art-c4cbf7180fce4d5d9fc2b47ff21ea979 |
| institution | OA Journals |
| issn | 2296-858X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-c4cbf7180fce4d5d9fc2b47ff21ea9792025-08-20T02:22:40ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-11-011110.3389/fmed.2024.14865031486503Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis CYuanji MaJiayi WangLingyao DuHong TangBackgroundRisk factors that influence the outcome of patients with chronic hepatitis C (CHC) are not fully understood. The systemic immune-inflammatory index (SII) is an independent prognostic factor for multiple diseases. However, the impact of the SII on the outcome of liver fibrosis is unclear.MethodsThis prospective real-world study enrolled patients with CHC treated with sofosbuvir/velpatasvir. Logistic regression models were used to investigate the relationship between the SII and the outcome of liver fibrosis in treatment-naive patients. Liver fibrosis was assessed using aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4).ResultsOf the 288 participants, the SII was 238.2 (153.0–358.2). The non-improved outcomes of liver fibrosis assessed with APRI (non-improved APRI) and FIB-4 (non-improved FIB-4) were 83.0 and 87.5%, respectively. Adjusted models showed that the SII was positively associated with non-improved APRI (adjusted OR (95% CI): 1.013 (1.009–1.017), p < 0.001) and FIB-4 (adjusted OR (95% CI): 1.004 (1.001–1.007), p = 0.012). Similarly, a higher SII was associated with a higher risk of non-improved APRI (adjusted OR (95% CI): 13.53 (5.60–32.68), p < 0.001) and FIB-4 (adjusted OR (95% CI): 5.69 (2.17–14.90), p < 0.001). The association with non-improved APRI was much more remarkable in patients with alanine aminotransferase <2 ULN, and the association with non-improved FIB-4 was remarkable in patients aged <50 years. Multiple imputation analyses confirmed the robustness of these results.ConclusionOur findings suggested that the SII was positively associated with non-improved outcomes of liver fibrosis in patients with CHC. These results need to be validated in large-scale prospective cohorts.https://www.frontiersin.org/articles/10.3389/fmed.2024.1486503/fullchronic hepatitis Cliver fibrosisrisk factorsystemic immune-inflammation indexoutcome |
| spellingShingle | Yuanji Ma Jiayi Wang Lingyao Du Hong Tang Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C Frontiers in Medicine chronic hepatitis C liver fibrosis risk factor systemic immune-inflammation index outcome |
| title | Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C |
| title_full | Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C |
| title_fullStr | Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C |
| title_full_unstemmed | Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C |
| title_short | Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C |
| title_sort | association between the systemic immune inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis c |
| topic | chronic hepatitis C liver fibrosis risk factor systemic immune-inflammation index outcome |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1486503/full |
| work_keys_str_mv | AT yuanjima associationbetweenthesystemicimmuneinflammationindexandtheoutcomeofliverfibrosisinpatientswithchronichepatitisc AT jiayiwang associationbetweenthesystemicimmuneinflammationindexandtheoutcomeofliverfibrosisinpatientswithchronichepatitisc AT lingyaodu associationbetweenthesystemicimmuneinflammationindexandtheoutcomeofliverfibrosisinpatientswithchronichepatitisc AT hongtang associationbetweenthesystemicimmuneinflammationindexandtheoutcomeofliverfibrosisinpatientswithchronichepatitisc |